39 related articles for article (PubMed ID: 10870049)
1. Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.
Barlesi F; Imbs DC; Tomasini P; Greillier L; Galloux M; Testot-Ferry A; Garcia M; Elharrar X; Pelletier A; André N; Mascaux C; Lacarelle B; Cheikh RE; Serre R; Ciccolini J; Barbolosi D
Oncotarget; 2017 Jul; 8(29):47161-47166. PubMed ID: 28525370
[TBL] [Abstract][Full Text] [Related]
2. Quality of Life in elderly patients with cancer.
Di Maio M; Perrone F
Health Qual Life Outcomes; 2003 Sep; 1():44. PubMed ID: 14525617
[TBL] [Abstract][Full Text] [Related]
3. Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997-2012).
Wouda RM; Miller ME; Chon E; Stein TJ
J Am Vet Med Assoc; 2015 Jun; 246(11):1230-7. PubMed ID: 25970220
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
Attia S; Traynor AM; Kim K; Merchant JJ; Hoang T; Ahuja HG; Beatty PA; Hansen RM; Masters GA; Oettel KR; Shapiro GR; Larson MM; Larson ML; Schiller JH
J Thorac Oncol; 2008 Sep; 3(9):1018-25. PubMed ID: 18758305
[TBL] [Abstract][Full Text] [Related]
5. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature.
Devlin JG; Langer CJ
Clin Lung Cancer; 2007 Mar; 8(5):319-26. PubMed ID: 17562231
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study.
Gridelli C; Perrone F; Gallo C; De Marinis F; Ianniello G; Cigolari S; Cariello S; Di Costanzo F; D'Aprile M; Rossi A; Migliorino R; Bartolucci R; Bianco AR; Pergola M; Monfardini S
Eur J Cancer; 1997 Mar; 33(3):392-7. PubMed ID: 9155522
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status.
Camerini A; Valsuani C; Mazzoni F; Siclari O; Puccetti C; Donati S; Rondini M; Tartarelli G; Puccinelli P; Di Costanzo F; Amoroso D
Ann Oncol; 2010 Jun; 21(6):1290-1295. PubMed ID: 19914959
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small-cell lung cancer.
Rossi D; Catalano V; Alessandroni P; Fedeli A; Fedeli SL; Giordani P; Baldelli AM; Casadei V; Ceccolini M; Ugolini M; Dennetta D; Catalano G
Clin Lung Cancer; 2007 May; 8(6):382-5. PubMed ID: 17562239
[TBL] [Abstract][Full Text] [Related]
9. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH
Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma: a phase II study.
Buccheri G; Ferrigno D
Cancer; 2000 Jun; 88(12):2677-85. PubMed ID: 10870049
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.
Curran MP; Plosker GL
Drugs Aging; 2002; 19(9):695-721. PubMed ID: 12381238
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
